What's Happening?
LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a $28 million Series A financing agreement with 5 Horizons Ventures, LLC. This funding will support the registrational STOP-Cdiff trial for SIDIPREV™, a novel non-antibiotic therapy aimed at preventing Clostridioides difficile infections. The trial is designed under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and targets high-risk hospitalized patients. C. difficile is a significant public health threat, causing 80 deaths daily in the U.S. SIDIPREV™ is an orally administered capsule that releases oxygen into the gastrointestinal tract, suppressing toxin production and reducing inflammation.
Why It's Important?
The financing marks a critical step in addressing the unmet need for preventive therapies against C. difficile, a deadly infection with no approved preventive treatments. The success of SIDIPREV™ could significantly impact hospital economics by reducing complications and costs associated with C. difficile infections. This development aligns with broader healthcare goals of improving patient outcomes and reducing healthcare costs. The investment by 5 Horizons Ventures highlights confidence in LPOXY's innovative approach and potential to unlock economic value for patients, hospitals, and investors.
What's Next?
LPOXY plans to launch the STOP-Cdiff trial in Q3 2026, with a goal to file for regulatory approval by 2029. The company is actively building its investment syndicate and engaging with other institutional investors to support its late-stage clinical strategy. The trial will evaluate SIDIPREV™'s efficacy and safety in approximately 500 patients, potentially paving the way for its commercialization.
